Biomedical Engineering Reference
In-Depth Information
376. Wagner, W.; Dullaart, A.; Bock, A. K.; Zweck, A. The Emerging Nanomedicine Landscape.
Nat. Biotechnol.
2006,
24,
1211-1217.
377. Kwong, B.; Liu, H.; Irvine, D. J. Induction of Potent Anti-Tumor Responses while Eliminating
Systemic Side Effects via Liposome-Anchored Combinatorial Immunotherapy.
Biomaterials
2011,
32,
5134-5147.
378. tenTije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological Effects of Formu-
lation Vehicles: Implications for Cancer Chemotherapy.
Clin. Pharmacokinet.
2003,
42,
665-685.
379. Krishnadas, A.; Rubinstein, I.; Onyuksel, H. Sterically Stabilized Phospholipid Mixed
Micelles: In Vitro Evaluation as a Novel Carrier for Water-Insoluble Drugs.
Pharm. Res.
2003,
20,
297-302.
380. Maeda, H. The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The
Key Role of Tumor-selective Macromolecular Drug Targeting.
Adv. Enzyme Regul.
2001,
41,
189-207.
381. Panyam, J.; Sahoo, S. K.; Prabha, S.; Bargar, T.; Labhasetwar, V. Fluorescence and Electron
Microscopy Probes for Cellular and Tissue Uptake of Poly(d, l-lactide-co-glycolide) Nanopar-
ticles.
Int. J. Pharm.
2003,
262,
1-11.
382. Wang, H.; Zhao, Y.; Wu, Y.; Hu, Y.; Nan, K.; Nie, G.; Chen, H. Enhanced Anti-tumor Effi-
cay by Co-delivery of Doxorubicin and Paclitaxel with Amphiphilic PEG-PLGA Copolymer
Nanoparticles.
Biomaterials
2011,
32,
8281-8290.
383. Chan, W. H.; Shiao, N. H.; Lu, P. Z. CdSe Quantum Dots Induce Apoptosis in Human Neu-
roblastoma Cells via Mitochondrial-dependent Pathways and Inhibition of Survival Signals.
Toxicol. Lett.
2006,
167,
191-200.
384. Drummond, D. C.; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadjopoulos, D. Optimizing
Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors.
Pharmacol. Rev.
1999,
51,
691-743.
385. Fetterly, G. J.; Straubinger, R. M. Pharmacokinetics of Paclitaxel-Containing Liposomes in
Rats.
AAPS Pharm. Sci.
2003,
5,
1-11.
386. Hoarau, D.; Delmas, P.; David, S.; Roux, E.; Leroux, J. C. Novel Longcirculating Lipid Nano-
capsules.
Pharm. Res.
2004,
21,
1783-1789.
387. Kamps, J. A.; Scherphof, G. L. Receptor Versus Non-receptor Mediated Clearance of Lipo-
somes.
Adv. Drug Deliv. Rev.
1998,
32,
81-97.
388. Mattiasson, B.; Borrebaeck, C. In
Enzyme Immunoassay
; Maggio, E. T., Ed.; CRC Press, Inc.:
Boca Raton, 1980; pp 295.
389. Papahadjopoulos, D.; Jacobson, K.; Nir, S.; Isac, T. Phase Transitions in Phospholipid Ves-
icles. Fluorescence Polarization and Permeability Measurements Concerning the Effect of
Temperature and Cholesterol.
Biochim. Biophys. Acta
1973,
311,
330-348.
390. Pastorino, F.; Brignole, C.; Marimpietri, D.; Sapra, P.; Moase, E. H.; Allen, T. M.; Ponzoni,
M. Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selec-
tively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice.
Cancer
Res.
2003,
63,
86-92.
391. Yan, X.; Kuipers, F.; Havekes, L. M.; Havinga, R.; Dontje, B.; Poelstra, K.; Scherpof, G. L.;
Kamps, J. A. A.M. The Role of Apolipoprotein E in the Elimination of Liposomes from Blood
by Hepatocytes in the Mouse.
Biochem. Biophys. Res. Commun.
2005,
328,
57-62.
392. Zhang, J. A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Develop-
ment and Characterization of a Novel Cremophor
®
EL free Liposome-based Paclitaxel (LEP-
ETU) Formulation.
Eur. J.Pharm. Biopharm.
2005,
59,
177-187.
